Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

Bibliography

• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69‐90
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11‐30
   PubMed Web of Science ®Google Scholar
• D'Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v116‐19
   PubMed Web of Science ®Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011;12(2):175‐80
   PubMed Web of Science ®Google Scholar
• Bepler G, Williams C, Schell M, et al. Molecular analysis-directed, international, phase III trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31(Suppl):abstract 8001
   Google Scholar
• Moran T, Cobo M, Domine M, et al. Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC). J Clin Oncol 2013;31:Suppl [abstract LBA8002]
   Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358(11):1160‐74
   PubMed Web of Science ®Google Scholar
• Patel R, Leung HY. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des 2012;18(19):2672‐9
   PubMed Web of Science ®Google Scholar
• Nakata A, Gotoh N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Ther Targets 2012;16(8):771‐81
   PubMed Web of Science ®Google Scholar
• Comis RL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist 2005;10(7):467‐70
   PubMed Web of Science ®Google Scholar
• Siegel-Lakhai WS, Beijnen JH, Schellens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 2005;10(8):579‐89
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21(12):2237‐46
   PubMed Web of Science ®Google Scholar
• Laurie SA, Goss GD. Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer. J Clin Oncol 2013;31(8):1061‐9
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123‐32
   PubMed Web of Science ®Google Scholar
• Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366(9496):1527‐37
   PubMed Web of Science ®Google Scholar
• Bell DW, Lynch TJ, Haserlat SM, et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23(31):8081‐92
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129‐39
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304(5676):1497‐500
   PubMed Web of Science ®Google Scholar
• Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101(36):13306‐11
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7(3):169‐81
   PubMed Web of Science ®Google Scholar
• Bria E, Milella M, Cuppone F, et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol 2011;22(10):2277‐85
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13(3):239‐46
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693‐703
   PubMed Web of Science ®Google Scholar
• Mok T, Yang JJ, Lam KC. Treating patients with EGFR-sensitizing mutations: first line or second line–is there a difference? J Clin Oncol 2013;31(8):1081‐8
   PubMed Web of Science ®Google Scholar
• Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009;361(10):958‐67
   PubMed Web of Science ®Google Scholar
• Kruczynski A, Delsol G, Laurent C, et al. Anaplastic lymphoma kinase as a therapeutic target. Expert Opin Ther Targets 2012;16(11):1127‐38
   PubMed Web of Science ®Google Scholar
• Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131(6):1190‐203
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561‐6
   PubMed Web of Science ®Google Scholar
• Forde PM, Rudin CM. Crizotinib in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2012;13(8):1195‐201
   PubMed Web of Science ®Google Scholar
• Gandhi L, Janne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012;18(14):3737‐42
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013
   Web of Science ®Google Scholar
• Pilotto S, Peretti U, Novello S, et al. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. Expert Opin Pharmacother 2013;14(5):597‐608
   PubMed Web of Science ®Google Scholar
• Comoglio PM. Pathway specificity for Met signalling. Nat Cell Biol 2001;3(7):E161‐2
   PubMed Web of Science ®Google Scholar
• Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63(19):6272‐81
   PubMed Web of Science ®Google Scholar
• Olivero M, Rizzo M, Madeddu R, et al. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer 1996;74(12):1862‐8
   PubMed Web of Science ®Google Scholar
• Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8(2):620‐7
   PubMed Web of Science ®Google Scholar
• Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63(19):6272‐81
   PubMed Web of Science ®Google Scholar
• Landi L, Minuti G, D'Incecco A, Cappuzzo F. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr Opin Oncol 2013;25(2):130‐6
   PubMed Web of Science ®Google Scholar
• Sequist LV, von PJ, Garmey EG, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011;29(24):3307‐15
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Novello S, Schiller JH, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 2012;13(5):391‐5
   PubMed Web of Science ®Google Scholar
• Available from: http://propthink.com/tivantinib-will-notmeet-primary-endpoint-phase-iii-trial-discontinued/2390)
   Google Scholar
• Spigel DR, Ervin T, Ramlau R, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011;29(Suppl):abstract 7505
   Google Scholar
• Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066): a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54(18):6342‐63
   PubMed Web of Science ®Google Scholar
• Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol 2011;6(10):1624‐31
   PubMed Web of Science ®Google Scholar
• Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066): a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011;6(5):942‐6
   PubMed Web of Science ®Google Scholar
• Hellerstedt B, Edelman G, Vogelzang N, et al. Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012;30(Suppl):abstract 7514
   Google Scholar
• Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One 2011;6(6):e20351
   PubMed Web of Science ®Google Scholar
• Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2010;2(62):62ps56
   PubMedGoogle Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2(62):62ra93
   PubMed Web of Science ®Google Scholar
• Kono SA, Heasley LE, Doebele RC, Camidge DR. Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 2012;12(2):107‐23
   PubMed Web of Science ®Google Scholar
• Buttitta F, Barassi F, Fresu G, et al. Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer 2006;119(11):2586‐91
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65(5):1642‐6
   PubMed Web of Science ®Google Scholar
• Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004;431(7008):525‐6
   PubMed Web of Science ®Google Scholar
• Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006;10(1):25‐38
   PubMed Web of Science ®Google Scholar
• De GJ, Teugels E, Geers C, et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012;76(1):123‐7
   PubMed Web of Science ®Google Scholar
• Mazieres J, Peters S, Lepage B, et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013;31(16):1997‐2003
   PubMed Web of Science ®Google Scholar
• Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30(8):863‐70
   PubMed Web of Science ®Google Scholar
• Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18(3):375‐7
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012;18(3):378‐81
   PubMed Web of Science ®Google Scholar
• Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18(3):382‐4
   PubMed Web of Science ®Google Scholar
• Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18(17):4570‐9
   PubMed Web of Science ®Google Scholar
• Ou SH, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in patients with advanced Non-Small Cell Lung Cancer (NSCLC) harboring ros1 gene rearrangement. Ann Oncol 2012;23(Suppl 9):abstract 2091
   Google Scholar
• Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62(23):6997‐7000
   PubMed Web of Science ®Google Scholar
• Dy GK, Hillman SL, Rowland KM Jr, et al. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: north Central Cancer Treatment Group Study N0326. Cancer 2010;116(24):5686‐93
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Gatzemeier U, Fossella F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009;27(26):4274‐80
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von PJ, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835‐42
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012;30(25):3084‐92
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1(1):44‐53
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949‐54
   PubMed Web of Science ®Google Scholar
• Naoki K, Chen TH, Richards WG, et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002;62(23):7001‐3
   PubMed Web of Science ®Google Scholar
• Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29(15):2046‐51
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Hanrahan AJ, Halilovic E, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008;68(22):9375‐83
   PubMed Web of Science ®Google Scholar
• Bansal A, Ramirez RD, Minna JD. Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene 1997;14(10):1231‐4
   PubMed Web of Science ®Google Scholar
• Bromberg-White JL, Andersen NJ, Duesbery NS. MEK genomics in development and disease. Brief Funct Genomics 2012;11(4):300‐10
   PubMed Web of Science ®Google Scholar
• Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68(14):5524‐8
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367(2):107‐14
   PubMed Web of Science ®Google Scholar
• Wallace EM, Lyssikatos JP, Yeh T, et al. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr Top Med Chem 2005;5(2):215‐29
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012;3(10):1068‐111
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Advances in targeting signal transduction pathways. Oncotarget 2012;3(12):1505‐21
   PubMedGoogle Scholar
• Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483(7391):570‐5
   PubMed Web of Science ®Google Scholar
• Milella M, Precupanu CM, Gregorj C, et al. Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects. Curr Pharm Des 2005;11(21):2779‐95
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Cheng KA, Hata AN, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23(1):121‐8
   PubMed Web of Science ®Google Scholar
• Tan N, Wong M, Nannini MA, et al. Bcl-2/Bcl-xL Inhibition increases the efficacy of Mek inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models. Mol Cancer Ther 2013;12(6):853‐64
   PubMed Web of Science ®Google Scholar
• Milella M, Estrov Z, Kornblau SM, et al. Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia. Blood 2002;99(9):3461‐4
   PubMed Web of Science ®Google Scholar
• Konopleva M, Contractor R, Tsao T, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006;10(5):375‐88
   PubMed Web of Science ®Google Scholar
• Konopleva M, Milella M, Ruvolo P, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia 2012;26(4):778‐87
   PubMed Web of Science ®Google Scholar
• Cragg MS, Jansen ES, Cook M, et al. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008;118(11):3651‐9
   PubMed Web of Science ®Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol 2010;5(10):1630‐6
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886): a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6(8):2209‐19
   PubMed Web of Science ®Google Scholar
• Holt SV, Logie A, Davies BR, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 2012;72(7):1804‐13
   PubMed Web of Science ®Google Scholar
• Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14(1):38‐47
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Kanai F, Hikiba Y, et al. Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 2005;65(11):4562‐7
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304(5670):554
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14(12):1351‐6
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Shigematsu H, Nomura M, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 2008;68(17):6913‐21
   PubMed Web of Science ®Google Scholar
• Ji M, Guan H, Gao C, et al. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer 2011;11:147
   PubMed Web of Science ®Google Scholar
• Kohno T, Takahashi M, Manda R, Yokota J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 1998;22(2):152‐6
   PubMed Web of Science ®Google Scholar
• Lee SY, Kim MJ, Jin G, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol 2010;5(11):1734‐40
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519‐25
   PubMed Web of Science ®Google Scholar
• Bleeker FE, Felicioni L, Buttitta F, et al. AKT1(E17K) in human solid tumours. Oncogene 2008;27(42):5648‐50
   PubMed Web of Science ®Google Scholar
• Do H, Solomon B, Mitchell PL, et al. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 2008;1:14
   PubMedGoogle Scholar
• Malanga D, Scrima M, De MC, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 2008;7(5):665‐9
   PubMed Web of Science ®Google Scholar
• Carpten JD, Faber AL, Horn C, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448(7152):439‐44
   PubMed Web of Science ®Google Scholar
• Wislez M, Spencer ML, Izzo JG, et al. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res 2005;65(8):3226‐35
   PubMed Web of Science ®Google Scholar
• Boffa DJ, Luan F, Thomas D, et al. Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 2004;10(1 Pt 1):293‐300
   PubMed Web of Science ®Google Scholar
• Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6(9):729‐34
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118(9):3065‐74
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7(7):1851‐63
   Google Scholar
• Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70(1):288‐98
   PubMed Web of Science ®Google Scholar
• Liu TJ, Koul D, LaFortune T, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009;8(8):2204‐10
   PubMed Web of Science ®Google Scholar
• Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008;1:20
   PubMed Web of Science ®Google Scholar
• Xu CX, Zhao L, Yue P, et al. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 2011;12(6):549‐55
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J Thorac Oncol 2012;7(8):1315‐26
   PubMed Web of Science ®Google Scholar
• Wojtalla A, Arcaro A. Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol Hematol 2011;80(2):278‐90
   PubMed Web of Science ®Google Scholar
• Cohen RB, Janne PA, Engelman JA, et al. A phase I safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor XL765 (SAR245409) in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol 2010;28:Suppl
   Google Scholar
• Kondapaka SB, Singh SS, Dasmahapatra GP, et al. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003;2(11):1093‐103
   PubMed Web of Science ®Google Scholar
• Lu W, Defeo-Jones D, Davis L, et al. In vitro and in vivo antitumor activities of MK-2206, a new allosteric Akt inhibitor. AACR Meeting Abstract; 2009
   Google Scholar
• Tolcher AW, Baird RD, Patnaik A, et al. A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol 2011;29(Suppl):abstract 300
   Google Scholar
• Hidalgo M, Buckner JC, Erlichman C, et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12(19):5755‐63
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T, Molina JR, Mandrekar SJ, et al. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. J Thorac Oncol 2012;7(5):919‐22
   PubMed Web of Science ®Google Scholar
• Soria JC, Shepherd FA, Douillard JY, et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20(10):1674‐81
   PubMed Web of Science ®Google Scholar
• Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16(23):5900‐7
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Harvey RD, Saba N, et al. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer. Cancer 2010;116(16):3903‐9
   PubMed Web of Science ®Google Scholar
• Vansteenkiste J, Solomon B, Boyer M, et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. J Thorac Oncol 2011;6(12):2120‐9
   PubMed Web of Science ®Google Scholar
• Price KA, Azzoli CG, Krug LM, et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 2010;5(10):1623‐9
   PubMed Web of Science ®Google Scholar
• Riely GJ, Brahmer JR, Planchard D, et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations. J Clin Oncol 2012;30(Suppl):abstract 7531
   Google Scholar
• Dancey JE, Bedard PL, Onetto N, Hudson TJ. The genetic basis for cancer treatment decisions. Cell 2012;148(3):409‐20
   PubMed Web of Science ®Google Scholar
• "Mutation Significance". Available from: https://confluence.broadinstitute.org/display/CGATools/MutSig)
   Google Scholar
• Vaske CJ, Benz SC, Sanborn JZ, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 2010;26(12):i237‐45
   PubMed Web of Science ®Google Scholar
• Ciriello G, Cerami E, Sander C, Schultz N. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res 2012;22(2):398‐406
   PubMed Web of Science ®Google Scholar
• Mullenders J, Bernards R. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 2009;28(50):4409‐20
   PubMed Web of Science ®Google Scholar
• Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10(5):351‐64
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376(9737):235‐44
   PubMed Web of Science ®Google Scholar
• Huang S, Holzel M, Knijnenburg T, et al. MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Cell 2012;151(5):937‐50
   PubMed Web of Science ®Google Scholar
• Whitehurst AW, Bodemann BO, Cardenas J, et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 2007;446(7137):815‐19
   PubMed Web of Science ®Google Scholar
• Swanton C, Marani M, Pardo O, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11(6):498‐512
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366(10):883‐92
   PubMed Web of Science ®Google Scholar
• Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci USA 2003;100(24):14229‐34
   PubMed Web of Science ®Google Scholar
• Celis JE, Gromov P. Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 2003;3(1):9‐15
   PubMed Web of Science ®Google Scholar
• Shankavaram UT, Reinhold WC, Nishizuka S, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007;6(3):820‐32
   PubMed Web of Science ®Google Scholar
• VanMeter A, Signore M, Pierobon M, et al. Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. Expert Rev Mol Diagn 2007;7(5):625‐33
   PubMed Web of Science ®Google Scholar
• Voshol H, Ehrat M, Traenkle J, et al. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS J 2009;276(23):6871‐9
   PubMed Web of Science ®Google Scholar
• Mueller C, Liotta LA, Espina V. Reverse phase protein microarrays advance to use in clinical trials. Mol Oncol 2010;4(6):461‐81
   PubMed Web of Science ®Google Scholar
• VanMeter AJ, Rodriguez AS, Bowman ED, et al. Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics 2008;7(10):1902‐24
   PubMed Web of Science ®Google Scholar
• Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012;104(3):228‐39
   PubMed Web of Science ®Google Scholar
• Zupa A, Improta G, Silvestri A, et al. A pilot characterization of human lung NSCLC by protein pathway activation mapping. J Thorac Oncol 2012;7(12):1755‐66
   PubMed Web of Science ®Google Scholar
• Nanjundan M, Byers LA, Carey MS, et al. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 2010;5(12):1894‐904
   PubMed Web of Science ®Google Scholar
• He Y, Zhou Z, Hofstetter WL, et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 2012;7(2):e31087
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Speer R, Pierobon M, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008;7(4):1508‐17
   PubMed Web of Science ®Google Scholar
• Improta G, Zupa A, Fillmore H, et al. Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J Proteome Res 2011;10(7):3089‐97
   PubMed Web of Science ®Google Scholar
• de Bono JS, Ashworth A. Translating cancer research into targeted therapeutics. Nature 2010;467(7315):543‐9
   PubMed Web of Science ®Google Scholar
• Di MM, Gallo C, De ME, et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 2010;67(2):127‐35
   PubMed Web of Science ®Google Scholar
• Goodwin R, Giaccone G, Calvert H, et al. Targeted agents: how to select the winners in preclinical and early clinical studies? Eur J Cancer 2012;48(2):170‐8
   PubMed Web of Science ®Google Scholar
• Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010;10(7):514‐23
   PubMed Web of Science ®Google Scholar
• Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials 2012;13:145
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011;1(1):44‐53
   PubMed Web of Science ®Google Scholar
• Liu PY, LeBlanc M, Desai M. False positive rates of randomized phase II designs. Control Clin Trials 1999;20(4):343‐52
   PubMedGoogle Scholar
• Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res 2007;13(3):781‐2
   PubMed Web of Science ®Google Scholar
• Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102(3):152‐60
   Google Scholar
• Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947‐57
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525‐31
   PubMed Web of Science ®Google Scholar
• Ferte C, Trister AD, Huang E, et al. Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. Clin Cancer Res 2013;19(16):4315‐25
   PubMed Web of Science ®Google Scholar
• Tsimberidou AM, Iskander NG, Hong DS, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18(22):6373‐83
   PubMed Web of Science ®Google Scholar